Trial Profile
A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Renal Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Dendritic cell-activated cytokine-induced killer cells (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Nov 2018 New trial record